Cannabichromene type compounds, or CBC type compounds are one of the 11 groups of phytocannabinoids found in the cannabis plant. CBC acts as an antagonist, or competition, to the cannabinoid receptors in our brain, to balance elevating effects of THC
Cannabigerol (CBG) is a type of cannabinoid obtained from the cannabis plant. It’s often referred to as the mother of all cannabinoids. This is because other cannabinoids are derived from cannabigerolic acid (CBGA), an acidic form of CBG.
Seven cannabinol-type, or CBN, compounds have been isolated from cannabis to date.
Cannabinol is the oxidized form of the molecule. Its carboxylic acid form is both present in the plant and formed through heating cannabinol. Alone, CBN has some mild psychoactivity through the CB2 receptor of the brain. CBN also acts as a CB1 receptor agonist, blocking THC from binding to those receptors. Theoretically this is how CBN balances the elevating effects of cannabis as well as boosts the effects Δ8-THC and Δ9-THC.
Delta-9-tetrahydrocannabinol is the principal psychoactive molecule of cannabis. The full chemical name for the psychoactive isomer is (−)-trans-Δ9-tetrahydrocannabinol. THC binds to both cannabinoid receptors of the brain. Although the chemical formula for THC describes multiple isomers (different orientation of the same molecule) the term THC is typically referring to the Delta-9-THC. Like most pharmacologically active plant compounds, THC is thought to be involved in the plant’s adaptation against insects, ultraviolet light, and environmental stress.
Delta-8-tetrahydrocannabinol has the same molecular skeleton as delta-9-THC but interacts differently with the receptors of the brain because it is an isomer, with flipped molecular orientation.
Delta-8-THC acts as competition to delta-9-THC at receptors of the brain altering the effects based on abundance.
Cannabidiol is the third most abundant chemical class type present in hemp landraces and early stage flowering cannabis. Currently, seven types of CBD have been isolated. Alone, CBD is non-psychotropic.Cannabidiol has been shown to positively modulate some of the neurotransmitter receptors of the brain, and as competition to the cannabinoid receptors in our brain. This theoretically balances the elevating effects of cannabis as well as boosts the effects of both Δ8-THC and Δ9-THC.